Human Safety Testing >> News and Events >> Webinar: Endocrine Disruptor Testing

Free Live Webinar

Sidebar Image

Challenges of Endocrine Disruptor Testing

Free Live Webinar: 2nd July 2019, 11:00 a.m.

 

Register here for the Eurofins Endocrine Disruptor Webinar

 

For some time now, endocrine disruptors have again come into focus of public interest. Therefore, public policy and regulatory decision making pushed the process of establishing testing programs and strategies to assess the safety of currently used chemicals with regard to their potential to interact with the endocrine system of man and wildlife, resulting in potential impacts on reproduction, growth, and/or development. Specifically, the USA, Japan, and EU have established testing approaches and regulatory frameworks with aim to assess the risks associated with chemicals that have endocrine disrupting properties (EDCs). These testing batteries were designed to work as a whole with all of the in vitro screening assays. The basis for selecting an assay to include in the battery involved main aspects: the capacity of an assay to detect estrogen, androgen, and/or thyroid mediated effects by various modes of action. For the determination of androgen and estrogen endocrine disruptors official guidelines for in vitro tests are available, whereas in vitro tests for detection thyroid disruptors are currently under evaluation and validation. Although these in vitro endocrine disruptor assays are proposed as components of a screening test battery, the results will be used in making weight-of-evidence decisions.


This webinar will discuss the following topics:

  • Which in vitro tests are available for Endocrine Disruptors?
  • What challenges are associated with in vitro tests?
  • How can the results of an in vitro test be evaluated?

 


Presentor:

Kristin Rödig, Study Director in vitro Pharmacology and Toxicology has gained more than 17 years’ experience in in vitro toxicology, assay development and biological safety assessment. She worked from July 2002 to February 2003 for GenPharmTox Biotech AG. During this period she was Study Director for in vitro genotoxicity and drug metabolism studies. Since March 2005 she worked for Eurofins BioPharma Product Testing Munich GmbH (former BSL Bioservice GmbH) in Planegg Germany. Kristin Rödig holds a graduate engineer in biotechnology from the university of applied science Weihenstephan.

 

 

 

 Kristin Roedig

 

If you want to stay informed about all events, offered by Eurofins Munich, please subscribe to our newsletter   or just follow us on Facebook or LinkedIn.